Evidence map›Paper›PMID 40938661›Full record

Trial reportHuman vaccines & immunotherapeutics2025

Phase 2 trial of personal dendritic cell vaccines in newly diagnosed glioblastoma: 3-year follow-up and correlations with survival.

Daniela A Bota, David E Piccioni, Christopher M Duma, Santosh Kesari, Jose A Carrillo, Renato V LaRocca, Robert D Aiken, Thomas H Taylor, Mehrdad Abedi, Rockelle M Robles and 4 more

Abstract readClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Human vaccines & immunotherapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Current Status and Evolution of Immunotherapy in Glioma Management.International journal of medical sciences · 2026
    Review
  6. Review
  7. A review of vaccinology andHuman vaccines & immunotherapeutics · 2025
    Review
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Daniela A BotaNeuro-Oncology, Chao Family Comprehensive Cancer Center, Comprehensive Brain Tumor Program, University of California Irvine, Orange, CA, USA.
David E PiccioniClinical Neurosciences and Neuro-Oncology, Moores Cancer Center, University of California San Diego, San Diego, CA, USA.
Christopher M DumaBrain Tumor Program, Hoag Neuroscience Institute, Hoag Hospital, Newport Beach, CA, USA.
Santosh KesariNeuro-Oncology, Pacific Neuroscience Institute, Saint John's Cancer Institute, Providence Saint John's Health Center, Santa Monica, CA, USA.
Jose A CarrilloNeurology and Neuro-Oncology, Saint John's Cancer Institute, Providence Saint John's Health Center, Santa Monica, CA, USA.
Renato V LaRoccaMedical and Neuro-Oncology, Norton Cancer Institute, Louisville, KY, USA.
Robert D AikenNeuro-Oncology, Atlantic Medical Group Neuroscience Institute, Overlook Medical Center, Summit, NJ, USA.
Thomas H TaylorDepartment of Neurology & Biostatistics Shared Resource, UCI Chao Family Comprehensive Cancer Center, Orange, CA, USA.
Mehrdad AbediDivision of Hematology/Oncology, UC Davis Comprehensive Cancer Center, University of California Davis, Sacramento, CA, USA.
Rockelle M RoblesRegulatory Affairs & Quality Assurance, Research and Development, AIVITA Biomedical, Inc., Irvine, CA, USA.
Krystal GoddingResearch and Development, AIVITA Biomedical, Inc., Irvine, CA, USA.
Hans S KeirsteadAdministration AIVITA Biomedical, Inc., Irvine, CA, USA.
Gabriel I NistorResearch and Development, AIVITA Biomedical, Inc., Irvine, CA, USA.
Robert O DillmanClinical, AIVITA Biomedical, Inc., Irvine, CA, USA.ORCID 0000-0002-2975-926X

Funding

Staff InvestigatorsP30CA093373 · NCI · UNIVERSITY OF CALIFORNIA DAVIS · PI Gina M Dayton · 2002 to 2026
$84.9M
Univ.of Calif., Irvine Cancer Center Support GrantP30CA062203 · NCI · UNIVERSITY OF CALIFORNIA-IRVINE · PI Melanie Funes · 1994 to 2026
$57.9M
NCI NIH HHS P30 CA062203NCI NIH HHS P30 CA093373
6 · The paper itself

Abstract

Survival of glioblastoma (GBM) patients is unsatisfactory. Adding patient-specific vaccines to standard therapy may improve outcomes. Autologous dendritic cells (DC) loaded with autologous tumor antigens (ATA) from short-term cell lines established from autologous tumor are a promising therapeutic vaccine strategy. DC-ATA vaccines were tested in a single-arm phase 2 trial in newly diagnosed GBM patients. Tumor tissue was collected during surgical resection. DC were differentiated from peripheral blood monocytes. Intent-to-treat enrollment took place before standard concurrent radiation therapy and temozolomide (RT/TMZ). DC-ATA was manufactured during RT/TMZ, then injected subcutaneously over 6 months concurrently with adjuvant TMZ. DC-ATA was reliably manufactured; treatment was well tolerated. Fifty-seven patients started vaccine therapy; 69% received all eight vaccine doses. The 10.7-month median progression-free survival (PFS) is 57% greater than the average of medians from standard treatment arms in six randomized trials that also enrolled patients before RT/TMZ. Disease control and overall survival (OS) dropped precipitously once DC-ATA was completed. Survival curves stratified by prognostic variables did not separate until after DC-ATA was discontinued. Multivariate analysis identified receipt of all eight planned vaccine injections,

Indexed as

Brain NeoplasmsCancer VaccinesDendritic CellsGlioblastomaAdultAgedAntigens, NeoplasmFemaleFollow-Up StudiesHumansMaleMiddle AgedSurvival AnalysisTemozolomideTreatment OutcomeYoung AdultAntigens, NeoplasmCancer VaccinesTemozolomideautologous tumor antigensdendritic cell vaccineGlioblastoma

Identifiers

PMID40938661
PMCPMC12439551

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.